Online inquiry

IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10129MR)

This product GTTS-WQ10129MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10129MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ251MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ11237MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ15795MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ4347MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ9045MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ6963MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ12133MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ12315MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MT203
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW